PYLARIFY success leads to maximum payment in first year BEDFORD, Mass. , May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable
Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period GAAP fully diluted net loss per share of $.04
BEDFORD , Mass. and INDIANAPOLIS , April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
BEDFORD, Mass. , April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 , to discuss its financial and operating results for the first quarter of 2023.
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer BEDFORD, Mass. , March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022,
Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans BEDFORD, Mass. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. (the Company) (NASDAQ: LNTH), a company
BEDFORD, Mass. , Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 , to discuss its financial and operating results for the fourth quarter and full
BEDFORD, Mass. , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings , Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease,
MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease BEDFORD, Mass. , Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
NORTH BILLERICA, Mass. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow
